Terms: = Pancreatic cancer AND CALCB, Calcitonin AND Prognosis
5 results:
1. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
Behdadnia A; Jeddi M
J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
[TBL] [Abstract] [Full Text] [Related]
2. Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of pancreatic Ductal Adenocarcinoma.
Saloman JL; Singhi AD; Hartman DJ; Normolle DP; Albers KM; Davis BM
Pancreas; 2018 Aug; 47(7):856-863. PubMed ID: 29975347
[TBL] [Abstract] [Full Text] [Related]
3. Neuroendocrine tumors producing calcitonin: characteristics, prognosis and potential interest of calcitonin monitoring during follow-up.
Nozières C; Chardon L; Goichot B; Borson-Chazot F; Hervieu V; Chikh K; Lombard-Bohas C; Walter T
Eur J Endocrinol; 2016 Mar; 174(3):335-41. PubMed ID: 26671974
[TBL] [Abstract] [Full Text] [Related]
4. Asymptomatic calcitonin-secreting tumor of the pancreas. A case report.
Delis S; Bakoyiannis A; Giannakou N; Tsigka A; Avgerinos C; Dervenis C
JOP; 2006 Jan; 7(1):70-3. PubMed ID: 16407623
[TBL] [Abstract] [Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma.
Leboulleux S; Baudin E; Young J; Caillou B; Lazar V; Pellegriti G; Ducreux M; Schaison G; Schlumberger M
Eur J Endocrinol; 1999 Mar; 140(3):187-91. PubMed ID: 10216512
[TBL] [Abstract] [Full Text] [Related]
